New combo therapy shows promise for older leukemia patients
NCT ID NCT02835222
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests whether adding the drug selinexor to standard chemotherapy helps older adults with untreated acute myeloid leukemia (AML) live longer. About 57 participants will receive either chemo alone or chemo plus selinexor, followed by maintenance therapy. The goal is to see if the combination improves survival and remission rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNTREATED ADULT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, 27157, United States
-
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.